Falk Gastro Info 7/2017

Video

Video course abdominal ultrasound

Examination of the liver: Portal vein branches

Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.

Please switch on your loudspeakers!

Link to Falk Mediacenter

Latest research in brief:

Bowel

Text:

Sandborn WJ et al, N Engl J Med. 2017;376(18):1723–36

Novel therapeutic approach for ulcerative colitis: The JAK inhibitor Tofacitinib is more effective than placebo to induce and maintain remission in patients with moderately to severely active ulcerative colitis.

Link to text

Text:

Feagan BG et al, Lancet. 2017;389(10080):1699–709

Selective IL-23 inhibition in Crohn’s disease: Risankizumab is more effective than placebo to induce remission in patients with active Crohn’s disease.

Link to text

Text:

Kugathasan S et al, Lancet. 2017;389(10080):1710–8

Prediction of complicated disease course in children with newly diagnosed Crohn’s disease: Risk stratification based on age, race, disease location and antimicrobial serologies as well as ileal gene expression allows prognosis for penetrating and structuring complications. Patients receiving early anti-TNF therapy have less penetrating complications.

Link to text

Liver Biliary Tracts

Text:

Bourlière M et al, N Engl J Med. 2017;376(22):2134–46

Hepatitis C: In two phase 3 trials, a total of 445 patients who did not have a sustained virological response (SVR) after treatment with regimens containing direct-acting antivirals (DAAs) were treated with sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks. Across HCV genotypes, the SVR rate was 96–98%.

Link to text

Text:

Charatcharoenwitthaya P et al, Liver Int. 2017;37(4):542–51
Chan AWH et al, J Gastroenterol Hepatol. 2017;32(3):667–76

Hepatitis B with concurrent non-alcoholic fatty liver disease (NAFLD): Two recent studies demonstrate that concurrent fatty liver is common in patients with hepatitis B; it is associated with severity of fibrosis and risk for hepatocellular carcinoma (HCC). However, antiviral treatment is not impaired by concurrent fatty liver.

Link to text

Text:

Serper M et al, Gastroenterology. 2017;152(8):1954–64

Hepatocellular carcinoma (HCC): A recent cohort study demonstrates the impact of timely subspecialist care by a hepatologist, medical oncologist, or surgeon as well as evaluation by more than one specialist and a multidisciplinary tumor board. These factors improve access to active HCC therapy as well as patient survival.

Link to text

Oesophagus Stomach Duodenum

Text:

Lebwohl B et al, BMJ. 2017;357:j1892

Long-term risk of gluten-free diet (GFD): This prospective cohort study demonstrates an increase of coronary heart disease in patients without celiac disease, possibly related to impaired intake of protective whole grain products.

Link to text

Text:

Kemppainen KM et al, Clin Gastroenterol Hepatol. 2017;15(5):694–702.e5

Gastrointestinal infections in early childhood increase risk of celiac disease: Gastrointestinal infections in early childhood increase risk of celiac disease in genetically predisposed children, which is also affected by HLA genotype, infant gluten consumption, breastfeeding and vaccination status against rotavirus.

Link to text

Text:

Friedman Flack K et al, Clin Gastroenterol Hepatol. 2017;15(5):682–90

Risk of major gastrointestinal bleeding related to anticoagulation therapy: Approx. 1 of every 12 bleedings is related to occult gastrointestinal cancer. Bleeding in these cases is most often chronic and associated with high morbidity.

Link to text

Pancreas

Text:

Mok SRS et al, Gastrointest Endosc. 2017;85(5):1005–13

Prophylaxis of post ERCP pancreatitis (PEP): Combination therapy of rectal indomethacin and infusion of lactated Ringer’s solution reduces the rate of PEP in high-risk patients as compared to infusion of saline alone.

Link to text

International Symposia and Workshops

Symposium 208

IX GASTRO-CONFERENCE (Part I)
Eosinophilic Esophagitis – Medical and Dietary Treatment

October 4 – 5, 2017, Berlin, Germany
Maritim Hotel Berlin, Stauffenbergstr. 26, 10785 Berlin, Germany

Program

Registration

Online registration

Symposium 209

IX GASTRO-CONFERENCE (Part II)
IBD 2017 – Therapeutic and Biological Barriers

October 6 – 7, 2017, Berlin, Germany
Maritim Hotel Berlin, Stauffenbergstr. 26, 10785 Berlin, Germany

Program